Tumor analysis is a key part of the cancer diagnostic workflow for all patients. Once a mass is removed from a patient, microscopic analysis is used to determine if it is cancer, as well as its characteristics and grade.
Typically, protein or DNA changes in sections of the sample are measured to determine the patient’s potential drug response. Samples with insufficient information, however, can be a major problem for pathologists and oncologists who are challenged with increasing numbers of therapy and test choices and interpretation of complex results.
To meet these challenges, GE Global Research has developed a new technology platform called MultiOmyxTM that enables analysis of dozens of proteins and DNA changes in a single tissue section. The result is in an image that tells exactly where the changes are in the tissue. This platform not only circumvents the challenge of limited samples, but also provides unprecedented insights into tumor biology.
Instead of being able to study one or two disease markers at a time, GE’s tumor analysis technology enables the study of up to 60 proteins in a single tumor slice. Also, GE’s technology allows pathologists and researchers to study the relationships between these different proteins or disease markers in ways not possible before, which could yield new insights into tumor behavior and provide a more complete picture of a patient’s cancer.
In 2010, GE acquired Clarient, one of the largest oncology diagnostic service businesses in the U.S. GE Global Research is transferring the MultiOmyx technology to Clarient Labs, where it will be provided as a research service and diagnostic platform. Clarient already has launched its first clinical test using this technology in July 2013, which will aid in the diagnosis of Hodgkin’s Lymphoma.
The growth of MultiOmyxTM highlights a new set of GE provided tools that deliver unprecedented insights into the makeup of cancer cells. The hope is that through greater understanding, we can help enable better treatments and outcomes for patients.